Document is current
Any future updates will be listed below
-
Authors
Shimose, Shigeo https://orcid.org/0000-0003-2068-8386
Saeki, Issei
Ito, Takanori
Takeuchi, Yasuto
Tani, Joji
Tomonari, Tetsu
Sasaki, Ryu
Sasaki, Kyo
Kakizaki, Satoru
Hatanaka, Takeshi
Iwamoto, Hideki
Tanabe, Norikazu
Yamamoto, Takafumi
Naganuma, Atsushi
Shirono, Tomotake
Kanayama, Yuki
Nishina, Sohji
Takayama, Tetsuji
Kobara, Hideki
Otsuka, Motoyuki
Kawashima, Hiroki
Takami, Taro
Kawaguchi, Takumi
,
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 17 January 2025
First Online: 28 February 2025
Declarations
:
: Shigeo Shimose received lecture fees from AstraZeneca and Eisai. Issei Saeki received lectures from AstraZeneca. Takanori Ito received personal fees from Chugai Pharmaceutical Co., Ltd. and AstraZeneca, and grants from Chugai Pharmaceutical Co., Ltd. outside the submitted work. Takeshi Hatanaka received lecture fees from Eisai, Japan. Hideki Iwamoto received lecture fees from Chugai Pharmaceutical Co., Ltd., and Eizai. Taro Takami received lecture fees from AstraZeneca and grants from Chugai Pharmaceutical Co. Ltd. Takumi Kawaguchi received lecture fees from ASKA Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., AbbVie GK., Eisai Co., Ltd., Novo Nordisk Pharma Ltd., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd. The authors have no conflicts of interest to declare.
: This study received approval from the Institutional Ethics Committee at the Kurume University School of Medicine (approval code: 24044).
: An opt-out approach was employed to obtain informed consent from patients.
